Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of “Hold” from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been given a consensus rating of “Hold” by the twenty-two research firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $124.15.

Several research firms recently weighed in on ZBH. Raymond James dropped their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Truist Financial restated a “hold” rating and issued a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Barclays dropped their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Finally, Stifel Nicolaus increased their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.95% of the stock is owned by insiders.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds and other institutional investors have recently bought and sold shares of the company. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet during the fourth quarter valued at about $25,000. Dunhill Financial LLC boosted its position in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the period. Menard Financial Group LLC bought a new stake in Zimmer Biomet during the 4th quarter worth approximately $30,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the third quarter valued at $35,000. Finally, Accredited Wealth Management LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth $36,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $111.72 on Friday. The company has a market cap of $22.24 billion, a P/E ratio of 25.11, a P/E/G ratio of 1.95 and a beta of 1.04. The firm’s fifty day moving average price is $106.62 and its two-hundred day moving average price is $106.96. Zimmer Biomet has a one year low of $97.69 and a one year high of $133.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the company posted $2.20 EPS. Equities analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.